New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases. KU Leuven Vlaams Instituut voor Biotechnologie
Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal, i.e. slowing of Alzheimer's disease (AD) progression. However, antibody therapy may not be the optimal therapeutic modality for AD prevention, as we will discuss in the context of the earlier small molecules described as "γ-secretase modulators" (GSM). We review here the structure, function, and pathobiology of γ-secretases, with a focus on how ...